Global Patent Index - EP 1037919 A1

EP 1037919 A1 2000-09-27 - PROTEINS FOR CANCER CELL SPECIFIC INDUCTION OF APOPTOSIS AND METHOD FOR ISOLATION THEREOF

Title (en)

PROTEINS FOR CANCER CELL SPECIFIC INDUCTION OF APOPTOSIS AND METHOD FOR ISOLATION THEREOF

Title (de)

PROTEINE ZUR KREBSZELLSPEZIFISCHEN INDUKTION VON APOPTOSE UND VERFAHREN FÜR IHRE ISOLIERUNG

Title (fr)

PROTEINES DESTINEES A PROVOQUER L'APOPTOSE SPECIFIQUE DE CELLULES CANCEREUSES ET PROCEDE POUR ISOLER CES PROTEINES

Publication

EP 1037919 A1 (EN)

Application

EP 98964142 A

Priority

  • US 9827108 W
  • US 99343297 A

Abstract (en)

[origin: WO9931135A1] The present invention provides the methods to isolate the proteins specifically induced apoptosis (programmed cell death) in prostate cancer cells (LNCAP), leukemia cells (HL-60), and breast cancer cells (MCF-70), but without effect in normal human lung fibroblast cells (CCD 39 Lu). P-1 has no effect on breast cancer cells. Five proteins have been isolated from the conditioned media of culture cells: (1) Apogen P-1: the proteins (Apogen P-1a, Apogen P-1b and Apogen P-1c) isolated from the conditioned medium of XC cells are able to induce apoptosis in prostate cancer cells (LNCAP) without effect in normal human lung fibroblast (CCD 39 Lu), colon cancer (T84), breast cancer (MCF-7) and leukemia (HL-60) cells. (2) Apogen P-2: the protein isolated from the conditioned medium of C3H1OT1/2 cells is able to induce apoptosis in prostate cancer cells (LNCAP) and breast cancer (MCF-7) without effect in normal human lung fibroblast (CCD 39 Lu) and colon cancer (T84) cells. (3) Apogen L: the protein isolated from the conditioned medium of XC cells is able to induce apoptosis in leukemia cells (HL-60), and breast cancer (MCF-7) without effect in normal human lung fibroblast (CCD 39 Lu), colon cancer (T84) and prostate cancer (LNCAP) cells. The invention may lead to the discovery of a novel class of anticancer drug that aims at prostate cancer, breast cancer, leukemia and other cancers by inducing apoptosis in cancer cells without affecting normal cells.

IPC 1-7 (main, further and additional classification)

C07K 14/47; A61K 38/17; C07K 14/435

IPC 8 full level (invention and additional information)

A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07K 14/47 (2006.01); C07K 14/71 (2006.01)

CPC (invention and additional information)

C07K 14/4747 (2013.01); C07K 14/71 (2013.01); A61K 38/00 (2013.01)

Citation (search report)

See references of WO 9931135A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9931135 A1 19990624; AU 1933099 A 19990705; CA 2325368 A1 19990624; CN 1314914 A 20010926; EP 1037919 A1 20000927; IL 136850 D0 20010614; JP 2002516821 A 20020611; MX PA00005954 A 20020918; NO 20003099 A 20000817; NO 20003099 D0 20000616; PL 343247 A1 20010730

INPADOC legal status


2003-01-29 [18W] WITHDRAWN

- Ref Legal Event Code: 18W

- Effective date: 20021204

2000-09-27 [17P] REQUEST FOR EXAMINATION FILED

- Ref Legal Event Code: 17P

- Effective date: 20000717

2000-09-27 [AK] DESIGNATED CONTRACTING STATES:

- Ref Legal Event Code: AK

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE